JPMorgan analyst Benjamin Rossi assumed coverage of Ardent Health (ARDT) with a Neutral rating and $20 price target The firm believes favorable trends across sales and expenses for managed care companies should allow for margin expansion in 2025, but considers the setup into 2026 to be more bearish, saying potential volume rollover and regulatory uncertainty following the November elections present an “imperfect storm” of payer mix headwinds and a negative overhang on go-forward sentiment for the hospitals.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners Announces Strong Q3 2024 Results
- Ardent Health reports Q3 EPS 19c, consensus 30c
- Ardent Health lowers 2024 EPS view to $1.18-$1.32 from $1.23-$1.37
- BofA shakes up ratings of healthcare stocks following Trump win
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls